With a whopping 7 approvals in the last two years, the field is alive with positive clinical read outs and the drive to get more life changing cell engager therapeutics to patients in indications of huge unmet need.

The timely 6th Cell Engager Therapeutics Summit returned once again to meet the needs of the community, focused on reaching new indications by expanding the target space and focusing our content to novel targets as well as continuing the push to focus on the translational challenges of developing cell engager therapies for solid and liquid tumours.

The summit united 100+ of colleagues from JNJ, Astellas, Amgen, CDR-Life, Regeneron, Immunocore, Crossbow Therapeutics and AstraZeneca in discovery and translational sciences, learn from clinical case studies to back translate, improve engineering by tuning affinity via adapting engager format and mitigating cytokine release syndrome. This was the one stop shop for all of the must have content dedicated to all engagers such as T-cell engagers, BiTe’s, gamma delta engagers and NK engagers.

As we look to prioritize the next generation intracellular targets, how you go about validating, discovering, and creating the next therapies to target them, the power of cell engager technology is clear. Attendees overcame their key challenges in developing cell engagers across three days of highly focused content - this wasn't one to miss!